Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer

Trial Identifier: D133FR00169
Sponsor: AstraZeneca
NCTID:: NCT04808050
Start Date: November 2021
Primary Completion Date: October 2022
Study Completion Date: October 2022
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Egypt Alexandria, Egypt
Egypt Cairo, Egypt
Egypt Giza, Egypt
Hong Kong Hong Kong, Hong Kong